NCT07167537 - A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Systemic Sclerosis (SSc)Primary Sjogren's Syndrome

Interventions

BIOLOGICAL

OL-CD19-GDT

OL-CD19-GDT will be given through IV bolus with ascending dose levels to determine the RDE and RP2D as specified in the protocol

Trial Locations (1)

RECRUITING

Beijing GoBroad Hospital, Beijing